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Abstract 
Background and Aims: 
Viscous solutions provide a superior submucosal cushion for endoscopic mucosal resection 
(EMR). SIC-8000 (Eleview, Aries Pharmaceuticals, La Jolla, Calif) is a commercially available 
FDA approved solution but hetastarch is also advocated. We performed a randomized trial 
comparing SIC-8000 to hetastarch as submucosal injection agents for colorectal EMR. 
Methods: 
This was a single-center double-blinded randomized controlled trial performed at a tertiary 
referral center. Patients were referred to our center with flat or sessile lesions measuring ≥15 mm 
in size. The primary outcome measures were the Sydney Resection Quotient (SRQ) and the rate 
of en bloc resections. Secondary outcomes were total volume needed for a sufficient lift, number 
of resected pieces, and adverse events. 
Results: 
There were 158 patients with 159 adenomas (84 SIC-8000 and 75 hetastarch) and 57 serrated 
lesions (30 SIC-8000 and 27 hetastarch). SRQ was significantly better in the SIC-8000 group 
compared with hetastarch group (9.3 vs 8.1, p=0.001). There was no difference in the proportion 
of lesions with en bloc resections. The total volume of injectate was significantly lower with 
SIC-8000 (14.8 mL vs 20.6 mL, p=0.038) 
Conclusions: 
SIC-8000 is superior to hetastarch for use during EMR in terms of SRQ and total volume 
needed, although the absolute differences were small.   
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Introduction 
Endoscopic mucosal resection (EMR) as traditionally performed involves submucosal injection 
of fluid underneath a sessile or flat lesion followed by snare resection. Saline solution has been a 
commonly used injection fluid for EMR. However, more viscous solutions provide a superior 
submucosal cushion1, 2. For example, in a randomized controlled trial succinylated gelatin was 
superior to saline solution3. Hetastarch has some properties that are similar to succinylated 
gelatin, is commonly used in the United States for EMR and in one trial produced longer 
submucosal elevation than saline solution4. Recently, 2 commercial submucosal injection fluids 
have been approved as devices by the U.S. Food and Drug Administration. The first was SIC-
8000 (Eleview, Aries Pharmaceuticals, Inc, San Diego, Calif), which was approved on the basis 
of a randomized controlled trial showing superiority compared with saline solution5. SIC-8000 
includes methylene blue as a contrast agent. ORIS gel (Boston Scientific, Marlborough, Mass) 
has been approved as a submucosal injection fluid with reference to SIC-8000 as a predicate 
device.  
 
At our center, we have generally used hetastarch as our submucosal injection fluid for EMR. 
Because hetastarch is less expensive than SIC-8000, we performed a randomized controlled 
clinical trial to compare hetastarch with SIC-8000. Our goal was to determine whether any 
advantages associated with SIC-8000 would justify its increased cost compared with hetastarch. 
 
 
Methods 
We performed a randomized controlled clinical trial comparing SIC-8000 to hetastarch. 
Hetastarch was purchased as Voluven (Fresenius Kabi Norge AS, Halden, Norway) and 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
methylene blue was added in a concentration to match SIC-8000, so as to blind the endoscopist 
and the technician to the material being injected. Both SIC-8000 and hetastarch were prepared in 
a separate area so as to keep the endoscopist and the technician blinded to the fluid, and they 
were delivered to the technician in identical syringes. SIC-8000 was obtained directly from the 
manufacturer. No epinephrine was added to either the SIC-8000 or the hetastarch. No external 
support was received for the study. 
 
The study was approved by the Institutional Review Board at Indiana University on September 
18, 2017. Patients were recruited between October 27, 2017 and December 6, 2018. The study 
was registered as NCT03350217 on October 19, 2017. Eligible patients were referred to the lead 
author (D.K.R.) for resection of lesions that were reported to be ≥15 mm in size. During 
colonoscopy, the actual maximum diameter of the lesion was measured using a Captivator II 
(Boston Scientific, Marlborough, Mass) snare of known diameter (either 15 or 20 mm in size). 
Lesions were required to be either sessile or flat in shape and ≥15 mm in size to be eligible for 
the study. Lesions were excluded if they were pedunculated or considered sufficiently scarred 
from one or more previous attempts at resection that the scarring process appeared likely to 
restrict lifting and to dominate the resection approach. The decision to include or exclude the 
lesion based on measurement and extent of scarring was made before the randomization was 
performed.       
 
We powered the study for all of the study lesions to be adenomas, and to be removed using 
electrocautery. All colonoscopies were performed using high-definition Olympus (Olympus 
Corporation, Center Valley, Pa) and in nearly all cases the instruments were adult colonoscopes. 
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All resections were performed by DKR. Lesions were assessed using the Narrow Band Imaging 
International Colorectal Endoscopic classification6 or NICE classification and were accurately 
recognized as adenomas vs sessile serrated polyps in all cases.  Serrated lesions in the study were 
generally removed by cold EMR7, other than a few very large serrated lesions early in the study 
that were removed by EMR using electrocautery. Serrated lesions were also randomized, but 
were not part of the primary comparison. The rationale for excluding serrated lesions is that the 
use of the small dedicated cold snares used to perform the cold EMR7 negated meaningful use of 
the Sydney Resection Quotient (SRQ) as a primary endpoint. In addition, the lead investigator 
holds the anecdotal opinion that perhaps because they have minimal to no submucosal fibrosis, 
serrated lesions have a tendency to lift well regardless of the injection fluid used. Thus, they are 
inferior to adenomas as a test of injection fluids for EMR.  The serrated lesions were randomized 
as an exploratory exercise. 
 
Lesions with endoscopic changes of deep submucosal invasion (NICE classification 3) were 
excluded from the study. Adenomas were removed after submucosal injection using snares of 15 
or 20 mm diameter and occasionally 10 mm. In general, resections were begun with 15 to 20 mm 
snares, and 10 mm snares were used as needed to remove small pieces remaining near the end of 
resection. Polyps were transected using Erbe (Erlangen, Germany) Endocut Q on the 2-1-4 
setting. Avulsion was performed if needed using Boston Scientific Radial Jaw 4 hot forceps on 
the Endocut I 3-1-3 setting. 
 
The primary endpoint for the study was the SRQ, defined as the size of the polyp in millimeters 
divided by the number of pieces resected. The second primary endpoint was the number of 
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subjects with en bloc resection of lesions. Secondary endpoints included the total volume of fluid 
injected, the volume injected for the initial lift, the number of reinjections, the number of 
resected pieces, the duration of the resection without the performance of clipping, the duration of 
the resection with clipping, the occurrence of adverse events, and the subjective measures of 
mound concentration, height, and duration each rated as excellent, satisfactory or poor. In 
general, if the injected fluid formed a concentrated submucosal mound with minimum lateral 
spread and lasted the duration of the resection it was considered excellent. At the other end of the 
spectrum, poor was considered little vertical lift with rapid lateral spread of fluid and dissipation 
of the fluid mound. In addition, the technician was asked to rate the ease of injection as very 
easy, easy, difficult or very difficult. All injections were made through a 23-gauge needle. Both 
the endoscopist and the technician were kept blinded to the fluid being used. 
  
Adenoma resection, which was entirely performed using EMR with electrocautery, was followed 
by clip closure of the EMR site if the defect size, location and accessibility allowed closure.  
Serrated lesions, which were largely removed by cold EMR, were not clip closed after resection 
unless electrocautery was used.  For both types of lesions, methylene blue served to stain the 
submucosa and allow identification of any muscle injury, and highlighted the perimeter of the 
lesion, which was considered particularly valuable for serrated lesions. 
Patients were contacted by telephone 30 days after EMR to ascertain adverse events. Delayed 
hemorrhage was defined as after release from the endoscopy suite that resulted in a visit to an 
emergency department, or hospitalization, or transfusions or repeat colonoscopy. Postcoagulation 
syndrome was defined as abdominal pain necessitating a visit to a provider that was associated 
with abdominal tenderness with or without fever or elevated white blood cell count. 
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Statistical analysis and sample size calculations:  
We aimed to enroll at least 150 adenomas in the study. Efficacy and safety of SIC-8000 injectate 
has only been reviewed in one previous study. Therefore, the planned sample size was not 
calculated using a statistical power analysis but was regarded as sufficient to repeat the 
objectives of the COSMO study 5 and satisfy the exploratory purposes of the present study. 
Patients were randomized using a computer generated sequence (simple randomization, 1:1 
ratio), which was sealed until the lesion was deemed eligible for enrollment. Comparison 
between the 2 groups for differences in patient level data was made using Wilcoxon rank sum 
tests and chi-squared tests for contiguous and categorical variables, respectively. For polyp level 
data, to account for correlation among multiple polyps per patient, comparisons were made using 
generalized estimating equation (GEE) models for continuous, ordinal, and binary outcomes. 
Serrated lesions were randomized as an exploratory analysis but not included in the primary 
analysis. A 5% significance level was used for all tests.  
 
If more than one lesion was eligible for inclusion in the study from a patient, all lesions were 
randomized to the same submucosal injection fluid used for the first lesion found. This was done 
to facilitate correct assignment of adverse events.  
 
No specific number of serrated lesions was targeted. The number of serrated lesions in the study 
reflects the number of eligible serrated lesions encountered in subjects who gave consent to 
participate from the onset of the study until the targeted number of adenomas was enrolled into 
the study.     
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Results 
Table 1 shows a comparison of demographic features, instruments used, and lesion size and 
location for the primary study set of adenomas, and separately for the serrated lesions. There 
were no differences in demographic features, bowel preparation quality scores, type or size of 
lesions between groups. There were 84 adenomas and 30 serrated lesions (mean size 26 mm and 
19 mm, respectively) randomized to injection with SIC-8000. The hetastarch group had 75 
adenomas and 27 serrated lesions (mean size 29 mm and 23 mm, respectively). 
 
Tables 2 and 3 show the primary and secondary endpoints for the adenomas, as well as for the 
serrated lesions. As noted above, because the serrated lesions were almost entirely (86%) 
removed using cold EMR using a dedicated cold snare, the SRQ was not evaluated for those 
patients. For adenomas, the SRQ was higher (superior) with SIC-8000 compared with hetastarch, 
9.3(6.2) versus 8.1(4.9); p = 0.001. The total injection volume with SIC-8000 was lower at 
14.8(13.1) mL versus 20.6(20.9) ml with SIC-8000; p = 0.038. There was a trend toward the 
number of reinjections of fluid and the number of resected pieces each being lower with SIC-
8000 (Table 2). Total resection time was numerically lower with SIC-8000 compared with 
hetastarch, but this trend also did not reach significance (Tables 2 and 3). There were no 
differences in the measures of mound height, quality or duration made subjectively by the 
endoscopist for SIC-8000 versus hetastarch.  
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Seventy-eight of 84 adenomas (93%) in the SIC-8000 arm were prophylactically clip closed 
compared with 64 of 75 adenomas (86%) in the hetastarch arm; p = 0.125.  Only the small group 
of serrated lesions removed by electrocautery were treated by clipping. The cold EMR sites after 
removal of most serrated lesions were not treated with prophylactic clipping. Intraprocedural 
bleeding was similar between the 2 study arms (Tables 2 and 3). There were 2 delayed bleeds, 
one in each arm. Both lesions were removed using electrocautery, and both patients went to the 
emergency department but neither was hospitalized or underwent colonoscopy or transfusion. 
There were no perforations in either arm. There was one type 3 deep mural injury in the sigmoid 
colon in the SIC-8000 arm, treated by clipping. The patient did not require hospitalization or 
surgery and had an uneventful 30-day follow-up.  
Discussion 
Submucosal injection fluids that are commercially available for use in the United States, 
including SIC-8000 and ORISE, are expensive compared with agents such as saline solution and 
hetastarch. In this double-blinded, randomized controlled trial, we found that SIC-8000, which 
has previously been shown to be superior to saline solution as a submucosal injection fluid5 was 
also superior to hetastarch. There were significant differences between SIC-8000 and hetastarch 
in the SRQ, and in the total amount of fluid injected. There were non-statistically significant 
trends toward superiority of SIC-8000 in the number of reinjections required, fewer numbers of 
resected pieces, and the resection duration. Thus, in this single investigator single-center trial, 
SIC-8000, administered in a blinded trial, was superior to hetastarch as a submucosal injection 
fluid for endoscopic mucosal resection. 
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Although differences between SIC-8000 and hetastarch were statistically significant, readers 
could reasonably ask whether the differences are clinically significant and justify the cost 
associated with SIC-8000. Currently the cost differences between SIC-8000 and hetastarch are 
reduced because both indigo carmine and methylene blue have become more expensive. Because 
one of these agents is typically added to hetastarch before injection, the cost of those agents is 
added to the cost of hetastarch. In contrast, SIC-8000 comes from the manufacturer with 
methylene blue added. 
 
Strengths of this study include the blinded, randomized design. Limitations include the single-
center single endoscopist design, which could limit the generalizability. A multicenter 
comparison of these agents would be appropriate. 
 
In summary, in a prospective double-blind, randomized controlled trial, we demonstrated that 
SIC-8000 was superior to hetastarch as a submucosal injection agent for colorectal EMR. 
Additional randomized controlled trials comparing available submucosal injection agents are 
needed. 
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Figure legend: 
Figure 1. Patient enrollment in the study. 
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Table 1. Patient and procedure characteristics in both groups 
 SIC-8000 Hetastarch P value 
Adenoma subset 
Number of patients (number of lesions) 66 (84) 63 (75) - 
Age, years (SD) 67.6 (8.3) 67.2 (9.4) 0.906 
Male gender, n (%) 33 (50) 34 (54) 0.652 
Boston Bowel Preparation Score, mean (SD) 8.7 (0.7) 8.5 (1.1) 0.761 
No fibrosis, n (%) 52 (62) 48 (64) 0.914 
No prior resection, n (%) 57 (68) 49 (65) 0.866 
Size of the lesion, mean (SD) 25.6 (11.4) 28.3 (14.5) 0.198 
Location of the lesion, n (%)   0.287 
Right colon 57 (68) 54 (72)  
Transverse colon 12 (14) 5 (7)  
Left colon 15 (18) 16 (21)  
Serrated subset 
Number of patients (number of lesions) 16 (30) 19 (27) - 
Age, years (SD) 64.8 (8.3) 60.8 (11.5) 0.361 
Male gender, n (%) 4 (25) 9 (47) 0.172 
Boston Bowel Preparation Score 8.4 (1.02) 8.8 (1) 0.057 
No fibrosis, n (%) 12 (86) 16 (89) 0.788 
No prior resection, n (%) 11 (85) 18 (95) 0.335 
Size of the lesion, mean (SD) 18.9 (6.3) 22.5 (15.4) 0.247 
Location of the lesion, n (%)   0.027† 
Right colon segment 17 (57) 15 (56)  
Transverse colon 12 (40) 5 (19)  
Left colon segment 1 (3) 7 (26)  
n, number of lesions; SD, standard deviation; †, Fisher exact 
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Table 2. Outcome measures for adenoma subset 
 SIC-8000 Hetastarch P value 
Number of patients (number of lesions) 66 (84) 63 (75) - 
Sydney Resection Quotient, mean (SD) 9.3 (6.2) 8.1 (4.9) 0.001 
En bloc resection, n (%) 66 (79) 61 (81) 0.515 
Injectate used for initial lift, mean (SD) 10.4 (5.4) 11.6 (7) 0.28 
Total injectate used, mean (SD) 14.8 (13.1) 20.6 (20.9) 0.038 
Number of reinjections, mean (SD) 0.61 (1.3) 1.01 (1.6) 0.074 
Number of resected pieces, mean (SD) 4.5 (5) 5.5 (5.3) 0.12 
Resection duration without clipping (minutes), 
mean (SD) 
14.8 (11.4) 16.02(13.9) 0.292 
Resection duration with clipping (minutes), mean 
(SD) 
17.3 (12.1) 19.4 (16.2) 0.235 
Mound concentration diameter 
Excellent 
Sufficient 
Inadequate 
 
43 (51) 
34 (40 
7 (8) 
 
38 (51) 
30 (40) 
7 (9) 
0.911 
Mound concentration height 
Excellent 
Sufficient 
Inadequate 
 
45 (54) 
31 (37) 
11 (13) 
 
41 (55) 
28 (37) 
6 (8) 
0.84 
Mound duration 
Excellent 
Sufficient 
Inadequate 
 
41 (49) 
31 (37) 
11 (13) 
 
40 (53) 
31 (41) 
4 (5) 
0.406 
Ease of injection 
Very easy 
Easy 
Difficult 
Very difficult 
 
39 (47) 
43 (52) 
1 (1) 
- 
 
33 (45) 
38 (51) 
3 (4) 
- 
0.686 
Adverse events    
Intraprocedural bleeding, n (%) 18 (22) 12 (16) 0.571 
Delayed bleeding, n (%) 1 (1.2) - 1† 
Postprocedure abdominal pain, n (%) - 1 (1.3) 0.488† 
n, number of lesions; SD, standard deviation; †, Fisher exact  
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Table 3. Outcome measures for serrated lesion subset 
 
 SIC-8000 Hetastarch P value 
Number of patients (number of lesions) 16 (30) 19 (27) - 
Sydney Resection Quotient, mean (SD) 12.3 (4.0) 11.1 (6.5) 0.702 
En bloc resection, n (%) 2 (7) 2 (7) 0.915 
Injectate used for initial lift, mean (SD) 7.1 (4.9) 8.7 (4.3) 0.123 
Total injectate used, mean (SD) 7.8 (5.7) 10.7 (8.8) 0.129 
Number of reinjections, mean (SD) 0.1 (0.31) 0.3 (0.9) 0.316 
Number of resected pieces, mean (SD) 7 (5.9) 8.2 (7) 0.413 
Resection duration without clipping (minutes), 
mean (SD) 
5.9 (4.2) 7.1 (9.1) 0.518 
Mound concentration diameter 
Excellent 
Sufficient 
Inadequate 
 
21 (70) 
7 (23) 
2 (7) 
 
16 (59) 
11 (41) 
- 
0.586 
Mound concentration height 
Excellent 
Sufficient 
Inadequate 
 
22 (73) 
6 (20) 
2 (7) 
 
17 (63) 
10 (37) 
- 
0.603 
Mound duration 
Excellent 
Sufficient 
Inadequate 
 
19 (66) 
10 (34) 
- 
 
18 (67) 
8 (30) 
1 (4) 
0.993 
Ease of injection 
Very easy 
Easy 
Difficult 
Very difficult 
 
13 (43) 
15 (50) 
2 (7) 
- 
 
13 (48) 
14 (52) 
- 
- 
0.634 
Adverse events 
Intraprocedural bleeding, n (%) 
Delayed bleeding, n (%) 
Postprocedure abdominal pain, n (%) 
 
- 
- 
- 
 
2 (7) 
1 (5.3) 
- 
 
0.181 
1† 
 
n, number of lesions; SD, standard deviation; †, Fisher exact  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Acronyms and abbreviations 
 
 
Endoscopic mucosal resection – EMR 
 
Millimeter – mm 
 
Sydney Resection Quotient – SRQ 
 
Douglas K. Rex – DKR 
 
Generalized estimating equation – GEE  
 
Milliliters – ml 
 
Standard deviation – SD  
